This year's OBIO Investment Summit features #UHNStartups Medly for Heart Failure, an innovation in cardiac health, and, in partnership with Stem Cell Network, @Inteligex2, a University Health Network company currently developing stem cell therapeutics for spinal cord injury.

Exciting to see this @ELSneuroscience textbook, led by Inteligex Founder Dr. Michael Fehlings, published! This book will be the go-to resource on spinal cord injury and spine trauma for years to come! #spinalcordinjury #SCI #trauma

A great recent publication discussing cell-based therapies for spinal cord injury, including lessons learned from clinical trials. It is an exciting era and we are proud to be at the forefront of this work. authors.elsevier.com/c/1f3d55FFzKqo…

Congratulations Dr. Ahuja!!

We are excited to be a part of this important Praxis Spinal Cord Institute program that helps bring exciting new products to those living with spinal cord injuries. Stay tuned for more updates!

I was fortunate to have the opportunity to be President of the International Neurotrauma Society and to organize the meeting in Toronto in 2018. It is great to be meeting in person in Berlin at another great INTS meeting. More updates to follow! Spine Program, University of Toronto Krembil Brain Institute

Inteligex Founding Member and CSO Dr. Mamad Khazaei recently won the Best Oral Presentation Award at the International Neurotrauma Symposium in Berlin!

Congrats @Inteligex founder & University of Toronto Prof, Michael G. Fehlings. He recently received: 🔹 2022 Apple award for excellence in spinal cord injury (SCI) rehabilitation literature 🔹nature's #1 author in the world for articles relevant to #SCI in the last 20 years lnkd.in/gaYEGBcE

It is great to be over in Israel as part of the UTEST, University of Toronto Innovation and Entrepreneurial Exchange Program! #innovation #celltherapy

Our Founder Michael G. Fehlings leading the 2022 Basic-Translational-Clinical Roundtable: Advancing Treatments to Drive Functional Restoration After Spinal Cord Injury: Developing a Pathway to Facilitate the Translational Pipeline at Society for Neuroscience Events !!

Inteligex Founder & President Dr. Michael Fehlings will be a featured presenter at the first-ever SCI Investor Symposium this June in San Diego!! SCI Investor Symposium Praxis Spinal Cord Institute

Next week Inteligex's CSO Dr. Mamad Khazaei will be in Boston to speak at the iPSC Manufacturing Summit! ipsc-manufacturing-summit.com

Last night we hosted the official launch event for Inteligex at JLABS Toronto. We are incredibly thankful to everyone who has supported us on our journey thus far and we are looking forward to big things in 2023!

Today's #MaRSHealthImpact2023 featured two University Health Network companies: recently launched company Inteligex, developing novel #celltherapies for CNS/SCI disorders & Nanogenix, commercializing #nanomedicine based novel therapies for cancer. #CommercializationLivesHere

A great Authority Magazine feature on our Founder & President, Dr. Michael Fehlings!

It is great to be in Boston for the BIO International Convention! Congratulations to #BIO2023 for putting together a fantastic event so far. Our team is in Boston for the remainder of the event - please reach out if you would like to connect to discuss our exciting cell platform!

Next stop for our team is the ISSCR Annual Meeting in Boston from June 14th to 17th. If you will be in attendance and would like to connect please reach out and let us know. We are always interested in discussing our technology and the future of Inteligex!

Great to have Dr. Khazaei in Boston to represent Inteligex at the International Society for Stem Cell Research meeting.

New publication from Inteligex team members Drs. Khazaei and Fehlings demonstrating that human spinal oligodendrogenic neural progenitor cells improve functional recovery in a cervical spinal cord injury model.